| goserelin acetate / Generic mfg. |
NCT00053911: Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer |
|
|
| Terminated | 3 | | Europe | anastrozole, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, goserelin acetate, tamoxifen citrate, adjuvant therapy | UNICANCER | Breast Cancer | 04/04 | | | |
NCT00002582: Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer |
|
|
| Completed | 3 | 6000 | Europe | CMF regimen, cyclophosphamide, doxorubicin hydrochloride, fluorouracil, goserelin acetate, leuprolide acetate, methotrexate, tamoxifen citrate, oophorectomy, radiation therapy | Institute of Cancer Research, United Kingdom, Cancer Research Campaign Clinical Trials Centre, Scottish Cancer Therapy Network, Yorkshire Regional Clinical Trials Research Unit | Breast Cancer | | 04/07 | | |
NCT00605267: Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment |
|
|
| Completed | 3 | 197 | Japan | Tamoxifen, NOLVADEX, Anastrazole (Arimidex), ARIMIDEX, ZD1033, Goserelin acetate (Zoladex), ZOLADEX | AstraZeneca | Breast Cancer | 11/09 | 12/10 | | |
NCT00429403: Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer |
|
|
| Terminated | 3 | 1 | Japan, US | Goserelin, Zoladex | M.D. Anderson Cancer Center | Breast Cancer | 07/10 | 07/10 | | |
NCT00047099: Combination Chemotherapy in Treating Women With Breast Cancer |
|
|
| Completed | 3 | 446 | Europe | cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, goserelin acetate, tamoxifen citrate, adjuvant therapy, radiation therapy | Ludwig-Maximilians - University of Munich | Breast Cancer | 02/12 | 03/12 | | |
|
|
|
|
PROOF, NCT00888082: Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy |
|
|
| Withdrawn | 3 | 102 | RoW | Goserelin acetate, Zoladex 3.6 mg Depot | AstraZeneca | Breast Cancer, Ovarian Function | 04/12 | 04/12 | | |
NCT01073865: Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer |
|
|
| Completed | 3 | 222 | Japan, RoW | ZD9393 (Zoladex) 10.8 mg, Zoladex, ZD9393 (Zoladex) 3.6 mg | AstraZeneca | Breast Cancer | 09/12 | 11/17 | | |
NCT01530607: Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer |
|
|
| Completed | 3 | 416 | US, RoW | Standard cyclophosphamide, Goserelin (Zoladex) | King Faisal Specialist Hospital & Research Center | Breast Cancer | 11/12 | 11/12 | | |
CRUK-OPTION, NCT00427245: Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer |
|
|
| Completed | 3 | 400 | Europe | cyclophosphamide, goserelin acetate, adjuvant therapy, fertility assessment and management, neoadjuvant therapy | Anglo Celtic Cooperative Oncology Group | Breast Cancer, Infertility, Menopausal Symptoms | | | | |
NCT00002580: Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer |
|
|
| Completed | 3 | 1000 | Europe | cyclophosphamide, fluorouracil, goserelin acetate, leuprolide acetate, methotrexate, tamoxifen citrate, conventional surgery, laparoscopic surgery, oophorectomy, radiation therapy | Scottish Cancer Therapy Network | Breast Cancer | | | | |
POF, NCT02483767: Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer |
|
|
| Completed | 3 | 98 | NA | goserelin, Gonadotropin-Releasing Hormone Agonist, standard chemotherapy, AC-P, TC, TA, TAC, FAC followed by T, AC | Peking Union Medical College Hospital | Breast Cancer | 11/16 | 11/16 | | |
NCT01712893: Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer |
|
|
| Completed | 3 | 216 | RoW | Zoladex, Zoladex = GnRHa,Goserelin | Fudan University | Breast Cancer | 08/17 | 08/17 | | |
| Completed | 3 | 56 | Europe | Tamoxifen, Tamoxifen and GnRH analogue, TRENATONE, ZOLADEX, Exemestane and GnRH analogue, AROMASIN, TRENATONE, ZOLADEX. | German Breast Group, Pfizer | Male Breast Cancer | 05/18 | 05/18 | | |
NCT03137368: A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP） |
|
|
| Enrolling by invitation | 3 | 300 | RoW | Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test, Tamoxifen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Pfizer | CYP2D6 Polymorphism | 10/23 | 10/23 | | |
NCT02132390: Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea |
|
|
| Not yet recruiting | 3 | 300 | RoW | Goserelin, Zoladex, Toremifene | Peking Union Medical College Hospital | Breast Cancer, Chemotherapy Induced Amenorrhea, Ovarian Function Suppression | 05/24 | | | |
SHPD002, NCT02221999: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2/3 | 250 | RoW | Paclitaxel, Taxol, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole | RenJi Hospital | Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer | 01/19 | 01/29 | | |
